Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 ... virus-related lower respiratory tract disease (RSV-LRTD) in adults aged 60 and older ...

ABL Bio previously entered into a global licensing agreement with GSK to develop treatments for neurodegenerative diseases. "ACIP recommends GSK’s RSV vaccine for at-risk adults 50 to 59" was ...

More than 35,000 cases of the mosquito-borne disease have been reported on the French Indian Ocean island since August 2024.

"These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research," said Tony Wood, GSK Chief Scientific ...

THURSDAY, April 17, 2025 (HealthDay News) — A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including respiratory syncytial virus (RSV ...

Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults.